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Synthesis, characterization and bioimaging of
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A fluorescent labeled Wells–Dawson type POM ({P2W17O61Fluo}) was newly synthesized and charac-
terized by a wide range of analytical methods. {P2W17O61Fluo} was functionalized with fluorescein
amine through a stable amide bond, and its long time stability was verified by UV/vis spectroscopic tech-
niques at physiologically relevant pH values. No significant impact on the cell viability or morphology of
HeLa cells was observed for POM concentrations up to 100 µg mL−1. Cellular uptake of fluorescent
{P2W17O61Fluo} was monitored by confocal laser scanning microscopy. POM uptake occurs mainly after
prolonged incubation times of 24 h resulting in different intracellular patterns, i.e. randomly distributed
over the entire cytoplasm, or aggregated in larger clusters. This direct monitoring strategy for the inter-
action of POMs with cells opens up new pathways for elucidating their unknown mode of action on the
way to POM-based drug development.
Introduction
Polyoxometalates (POMs) have been attracting interdisciplinary
research interest for decades due to their virtually unlimited
structural flexibility which provides access to a wide range of
key material properties.1–5 The high bioactive potential of
POMs has been under intense investigation since the 1980s,
and their observed antibacterial, anticancer and antiviral
activity opens up new perspectives for the development of low-
cost and tuneable inorganic drugs, e.g. against new viral
threats and the increasing problem of bacterial resistances.6–11
However, the multitude of empirical bioactivity data
derived from POM-based in vitro and in vivo studies12 did not
afford a proportional degree of insight into their biochemical
pathways. Localization of POMs in cells and clarification of
their metabolization after endocytosis would provide essential
information for understanding their modes of action. Tracking
of POMs in cellular environments is furthermore indispens-
able to control their adverse effects, such as cytotoxicity, and
to circumvent instability under physiological conditions. Over
the past few years, an increasing number of drug delivery
approaches for POM encapsulation has been developed, such
as efficient anticancer POM–liposome composites.13–16 Never-
theless, informed development of POM-based drug prototypes
is delayed by a lack of direct visualization techniques.
Our recent studies were thus focused on nanocapsules
based on bioactive POMs and various chitosan derivatives, pre-
ferably carboxymethyl chitosan (CMC) and trimethyl chitosan
(TMC). These nanocomposites combine stability under
ambient conditions with significantly lowered POM cyto-
toxicity.17,18 Next, we demonstrated that POM–CMC composites
can be safely shuttled into cancer cells. For the first time, we
directly observed cellular uptake of bioactive POM composites:
complementary CLSM (confocal laser scanning microscopy)
and TEM (transmission electron microscopy) techniques on
labeled and unlabeled nanocomposites, respectively, revealed
that they are taken up within less than 1 h with a strong prefer-
ence for the perinuclear region of HeLa cells.19 As the next step
towards elucidation of biochemical POM routes, we here
present new evidence for cellular uptake of pristine POMs.
Microscopic tracking of fluorescent POMs containing
lanthanoid heteroatoms, such as europium or gadolinium,
appears to be the most straightforward approach at first
glance. Unfortunately, it cannot be directly applied in biologi-
cal media, because the luminescence of Ln-containing POMs
can only be monitored in the solid state, whereas it is
quenched in aqueous solutions by hydrate layers.20,21 This
renders attachment of a fluorescent dye to bioactive POMs a
very promising strategy. However, derivatization of POMs with
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organic residues remains a challenge, and only a few
approaches hitherto have been established to connect POM
moieties with fluorescent dyes.22–24 Moreover, the instability of
many POMs at physiological pH severely limits the number of
suitable candidates for such labeling reactions.
Viable routes towards stable organic functionalization of
POMs have been published by Bareyt et al. and Carraro
et al.25,26 The first approach introduces POMs equipped with
Sn-organyl derivatives carrying a carboxyl group, and the latter
study modifies POMs with Si-organyls containing amino
groups. Tin-functionalized POMs have furthermore been evalu-
ated for their inhibitory potential against protein kinase
CK2.27 Here, we employ the Sn-organyl route via carboxyl-func-
tionalized POMs for coupling reactions with fluorescein
through amide bond formation.28,29 The target POM TBA6K[α2-
P2W17O61{Sn(CH2)2CONHC20H11O5}] contains the lacunary [α2-
P2W17O61]
10− derivative of the Wells–Dawson polyanion
[P2W18O62]
6−, which is a prototype bioactive POM. It excels
through antibacterial activity against resistant strains and has
been widely investigated and derivatized as an anti-HIV
agent.30–32 Insulin mimetic33 and neurite outgrowth effects34
furthermore amplify the bio-medical spectrum of Wells–
Dawson-type POMs. Concerning their lacunary derivatives,
interaction of [P2W17O61]
10− with human serum albumin
(HSA) has been studied.35 Zr-substituted derivatives have
recently been identified as selective catalysts for peptide bond
hydrolysis,36 while gadolinium introduction opens up new pos-
sibilities for MRI contrast agents.37,38
In the following, we present the synthesis and characteriz-
ation of fluorescent labeled Wells–Dawson POMs, followed by
direct monitoring of their interaction with cancer cells.
Results and discussion
Synthesis of fluorescein labeled POMs
Our route towards fluorescent labeled POMs started from the
pioneering approach of Bareyt et al. for the versatile
functionalization of the lacunary Wells–Dawson heteropoly-
anion K10[α2-P2W17O61] via a tin organyl moiety equipped with
a reactive carboxyl group.25 As this carboxyl “anchor” can be
easily modified into esters or amides, we labeled the POM with
fluorescein through amide bond formation. EEDQ was
employed as a coupling agent to combine fluorescein amine
and the derivatized POM into TBA6K[α2-P2W17O61{Sn(CH2)2-
CONHC20H11O5}] (labeled POM henceforth abbreviated as
{P2W17O61Fluo}, cf. Fig. 1).
Characterization of fluorescein labeled POMs
Structure and stability. Thermogravimetric analysis of
{P2W17O61Fluo} showed that the fluorescent labeled POM con-
tains 10 aqua ligands and remains stable up to 300 °C, fol-
lowed by decomposition of the organic moiety at higher
temperatures. Elemental analysis of {P2W17O61Fluo} provides
strong evidence for successful fluorescein coupling with negli-
gible differences between analytical and calculated C and H
contents and a slight deviation (around 0.4) for N. Reaction
progress was furthermore monitored via 31P NMR (Fig. S1†).
The structural integrity of the precursors and the final com-
pound was verified by NMR spectroscopy (Fig. S2 and S3†).
Stability of {P2W17O61Fluo} was investigated under con-
ditions as close as possible to cell culture media (PBS, pH 7.2).
Analogous to cellular uptake experiments, the labeled POM
was first dissolved in DMSO to yield a 0.3% (v/v) DMSO in PBS
solution after combination of both media. Interestingly,
{P2W17O61Fluo} did not precipitate upon PBS addition, thus
eliminating the need for subsequent ion exchange reactions
prior to cellular uptake tests.
The solubility of TBA-{P2W17O61Fluo} in aqueous media
strongly depends on their components in combination with
the pH value: dissolution was observed in PBS or cell culture
medium (DMEM) at pH values above 7, whereas precipitation
sets in at lower pH values or in water.
The UV/vis spectrum of {P2W17O61Fluo} in PBS (Fig. 2)
clearly indicates its stability around neutral pH conditions
through monitoring of the characteristic POM absorption
bands, i.e. two charge-transfer shoulders (O → W) at 257 and
289 nm and a fluorescein-based absorption with a maximum
at 458 nm (Fig. 2b) which overlaps with POM bands in the UV
region. These characteristic POM absorption bands did not
undergo significant changes at any wavelength over a period of
5 days (Fig. S4†). These results agree well with the previously
observed stability of a representative Sn-substituted Wells–
Dawson type POM in physiological media.25
Fig. 2 UV/vis spectrum of {P2W17O61Fluo} in PBS.
Fig. 1 Synthesis of TBA6K[α2-P2W17O61{Sn(CH2)2CONHC20H11O5}] labeled with
fluorescein amine.
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FT-IR spectroscopy. FT-IR spectra of fluorescein amine,
K10[α2-P2W17O61] ({P2W17O61}), TBA6K[α2-P2W17O61{Sn(CH2)2-
COOH}] ({P2W17O61Sn}) and {P2W17O61Fluo} are compared in
Fig. 3. Functionalization with the tin organyl moiety affects the
band positions of the POM scaffold (Fig. 3b and c), and two
new bands appear at 1719 and 1485 cm−1 which can be attrib-
uted to the carboxyl group and the vibrations of the organic
side chain. Key vibrations of TBA6K[α2-P2W17O61{Sn(CH2)2-
COOH}] are summarized in Table S1,† and the characteristic
bands of the aryl moiety (e.g. at 1400, 1382, 1327, 1280, 1256,
1242, 1215 and 1175 cm−1) illustrate the successful coupling of
POM and fluorescein amine. The labeled POM withstands
heating to 200 °C as can be seen from FT-IR spectra (Fig. S5†).
In vitro cell viability tests. Fluorescein labeled POMs (50
and 100 µg mL−1) were tested for cytotoxicity vs. HeLa cells
with cell viability (MTT) assays (Fig. 4). Cells incubated under
conditions described in the Experimental section (below) did
not display significant viability changes in comparison with
controls grown in cell culture media. Experiments with the
water-soluble sodium salt of {P2W17O61Fluo} and with TBA-
{P2W17O61Fluo} led to comparable results. All in all, no signifi-
cant toxicity of {P2W17O61Fluo} towards HeLa cells could be
detected.
Cellular uptake of fluorescent POMs
Cellular uptake tests were performed on HeLa cells which were
incubated with 50 and 100 µg mL−1 TBA-{P2W17O61Fluo} and
Na-{P2W17O61Fluo}, respectively, for 1, 5 and 24 h (for details
cf. Experimental section). Both TBA- and Na-{P2W17O61Fluo}
display related time-dependent uptake kinetics: only very few
particles are visible in the cells after 1 h and 5 h of incubation
(Fig. S8†), but prolonged treatment (24 h) led to uptake of
larger POM quantities (Fig. 5). Compared to our preceding cel-
lular uptake studies on fluorescent labeled POM nanocompo-
sites, pristine POMs display similar uptake behavior, albeit
with a slight delay.18,19
POM uptake was monitored by CLSM on HeLa cells, and
Fig. 5 shows the cells after 24 h of incubation with fluorescent
{P2W17O61Fluo}.
Fig. 4 MTT assays of TBA- and Na-{P2W17O61Fluo}.
Fig. 5 (a) Confocal picture of HeLa cells with stained nucleus (blue) incubated
with 50 µg mL−1 TBA-{P2W17O61Fluo} (green) for 24 h; (b) confocal picture
merged with the DIC image showing the intact cell morphology.
Fig. 3 FT-IR spectra of (a) fluorescein amine, (b) {P2W17O61}, (c) {P2W17O61Sn}
and (d) {P2W17O61Fluo}.
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POM localization exhibits two different patterns, namely
random distribution or formation of large clusters in the cell
cytoplasm. It is currently not clear whether this is the result of
e.g. alternative internalization modes or intracellular proces-
sing pathways. Colocalization with mitochondria was not
observed, but cluster accumulation might occur in trafficking
or recycling vesicles. However, distributions of {P2W17O61Fluo}
signals were notably different from those found in our pre-
vious study with fluorescent labeled POM nanocomposites
that featured mainly perinuclear localization.19 Given that
TBA- and Na-salts of {P2W17O61Fluo} did not differ signifi-
cantly with respect to cellular uptake, the countercation does
not appear to play a crucial role in the process.
Location of {P2W17O61Fluo} within HeLa cells after 24 h of
incubation was furthermore verified by z-stack recordings.
Section views focusing on a selected POM cluster located in all
planes are shown in Fig. S6a, and Fig. S6b† provides a 3D
maximum projection visualizing the amounts and cluster
shapes of POMs within cells. Note that strong and homo-
geneous POM uptake is not equally displayed by all cells. This
may be due to active POM uptake and might thus reflect
inhomogeneous activity of the cell population, but further
investigations using immunocytochemistry methods are
required to track endocytotic pathways.
Fluorescent labeled POMs were never found to enter the
nucleus, regardless of concentration or incubation time. This
key observation does not support any active interaction of
POMs with nuclear DNA and their role as possible mutagens
under the given conditions. This also sheds new light on the
antiviral properties and additional bio-medical effects of
Dawson-type POMs which are probably proceeding without
direct POM–DNA interactions.31
Earlier, Cibert and Jasmin employed different spectroscopic
methods to demonstrate that ammonium-21-tungsto-9-anti-
monate (HPA-23) is capable of entering C3HBi fibroblasts.39
The authors furthermore concluded from these indirect obser-
vations that POMs enter cells, but do not aggregate in any cell
organelles. Our results newly reveal the presence of large POM
aggregates inside cells. While we can only exclude their co-
localization with mitochondria on the basis of our study,
nothing is currently known with respect to other organelles.
However, it may be speculated that POMs (dispersed or in clus-
ters) are encapsulated within membrane-bound vesicles, as
reported for silica nanoparticles by Besic Gyenge et al.40
As expected from MTT assays, differential interference con-
trast (DIC) images (Fig. 5b) demonstrate intact cell mor-
phologies after POM uptake in line with control samples
(Fig. S7†). However, one noteworthy difference is evident: cells
containing large POM aggregates generally displayed more vacu-
oles than those without such POM clusters or control cells.
However, confocal images also show that these vacuoles do not
contain POMs. Their frequent formation may indicate a certain
extent of stress on the cells. Whereas our microscopic obser-
vations correspond with preceding reports on vacuole appear-
ance in POM-treated cells by Boudinot et al.,41 we could not
confirm their hypothesis of POM location within such vacuoles.
We furthermore observed POM-containing HeLa cells
during telophase in the late stages of cell cleavage (Fig. 6).
Labeled POM aggregates are found over the entire cell cyto-
plasm and they are equally distributed between the two
emerging daughter cells. This points to a certain persistence of
POMs within the cellular environment, wherein they are rather
accumulated and redistributed than quickly degraded.
Furthermore, POM uptake by HeLa cells was verified by
ICP-MS analysis on lyophilized samples (Table 1), and protein
contents were determined in parallel (for details cf. Experi-
mental below). Control experiments with or without fluore-
scein amine in the absence of POMs did not display any
tungsten above the analytical detection limits, i.e. background
concentrations in cells can be excluded. After treatment with
{P2W17O61Fluo}, however, tungsten contents of HeLa cells
sharply raised to ca. 3.28 μg mg−1 protein or 0.98 pg per cell,
respectively. Interestingly, comparable tungsten amounts were
found after treatment of HeLa cells with unlabeled POM
(K6[P2W18O62]·16H2O) (2.70 μg mg−1 protein corresponding to
0.81 pg W per cell). These results indicate that fluorescein
amine-labeling does not substantially influence the POM
uptake process. Most importantly, the cellular uptake of tung-
sten species provides strong evidence that the observed fluore-
scence signals (Fig. 5 and 6) indeed arise from intact
{P2W17O61Fluo}, given that its stability in neutral media is
evident from spectroscopic data (Fig. 2 and S4†).
Fig. 6 Confocal picture merged with the DIC image of a HeLa cell during clea-
vage incubated with 50 µg mL−1 TBA-{P2W17O61Fluo} (green; nucleus: blue) for
24 h.
Table 1 Tungsten contents in HeLa cells incubated for 24 h with 100 µg mL−1
TBA-{P2W17O61Fluo} (POM-Fluo), unlabeled POM (K6[P2W18O62]·16H2O) or









Untreated control 4.12 0.00a 0.00a 0.00a
POM 3.88 2.70 0.81 1.07
POM-Fluo 3.12 3.28 0.98 1.31
Fluorescein amine 4.02 0.00a 0.00a 0.00a
a 0 or below detection limit. b Total protein content of HeLa cells was
assumed to be 300 pg per cell.42
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To the best of our knowledge, cellular uptake of POMs has
never been determined before with comparable accuracy.
Reference data for cellular contents of physiologically less
abundant transition metal ions are generally rather rare.
Nevertheless, we compared the above results to different metal
uptake scenarios, starting with gallium uptake by HL 60 cells
as a representative example of a non-essential metal ion.43
Here, considerably lower cellular metal contents of 3.5 × 10−4
pg Ga per cell in comparison with the above tungsten concen-
trations were observed. Next, we found our tungsten contents
to be in the same range as platinum contents in HeLa cells
after treatment with cisplatin (1.12 ± 0.07 μg Pt mg−1
protein)44 which indicates that POM levels in HeLa cells might
be of interest for further studies. Finally, HeLa cells treated
with magnetodendrimers for magnetic resonance tracking
contained much more iron (13.6 ± 5.5 pg iron per cell) com-
pared to POM uptake.45
Conclusions
New fluorescent labeled Wells–Dawson POMs were obtained
through connection of functionalized lacunary POMs with
fluorescein via amide linkage. Specifically, K10[α2-P2W17O61]
was equipped with a carboxy-functionalized tin organyl
which subsequently formed a stable amide bond with fluore-
scein. Fluorescent labeling of TBA6K[α2-P2W17O61{Sn(CH2)2-
CONHC20H11O5}] was verified with a wide arsenal of analytical
methods including elemental analysis, FT-IR, NMR, and UV/
vis spectroscopy. {P2W17O61Fluo} is soluble in PBS and cell
culture medium (DMEM) at physiologically relevant pH values.
Stability of {P2W17O61Fluo} over several days under cell test
conditions was established by UV/vis spectroscopy. No cyto-
toxicity of {P2W17O61Fluo} towards HeLa cells was observed for
concentrations up to 100 µg mL−1 regardless of the POM coun-
tercation, and cell viability as well as morphology were not sig-
nificantly changed.
Cellular uptake tests furthermore provided the first evi-
dence of localization of pristine POMs within cells, and two
different intracellular distribution patterns were observed.
Fluorescent POMs may either appear as randomly dispersed
signals over the entire cytoplasm, or aggregated in clusters,
which may point towards an organelle-related localization site.
Importantly, we found no evidence for POMs entering the
nucleus for various concentrations and incubation times,
which calls for new in-depth investigations into their empiri-
cally observed antiviral and anticancer activity. Tungsten con-
centrations in HeLa cells are around 0.98 and 0.81 pg W per
cell after treatment with labeled and pristine POMs, respecti-
vely. Consequently, FITC-labeling does not strongly influence
the POM uptake process. The POM contents appear to be in a
promising range for further bioactivity studies which are cur-
rently underway.
All in all, we introduce new fluorescent labeled POMs as
important monitoring agents to directly track their bio-
medical modes of action. This approach opens up innovative
perspectives to tailor low-cost POM drugs through unprece-




All used reagents were purchased from Sigma-Aldrich or Acros
as ACS reagents and used as received.
Synthesis of TBA6K[α2-P2W17O61{Sn(CH2)2CONHC20H11O5}]
EEDQ (19.2 mg, 0.08 mmol, 1.5 eq.) was dissolved in aceto-
nitrile (5.5 mL) under reflux (80 °C) in a N2 atmosphere.
TBA6K[α2-P2W17O61{Sn(CH2)2COOH}] (0.30 g, 0.05 mmol) was
added and the mixture was stirred for 15 min. Afterwards,
fluorescein amine (53.7 mg, 0.16 mmol) was added and the
solution was refluxed at 90 °C for 24 h whereupon the color
changed from yellow to orange. Reaction progress was moni-
tored by 31P-NMR. After completion of the reaction, the solvent
was removed under vacuum and the orange oily residue was
taken up in a minimum of acetonitrile. The product was preci-
pitated through THF addition and collected by filtration. After
several washing steps with THF the product was dried in vacuo.
Yield: 218 mg (0.03 mmol, 69%, orange solid).
FT-IR (KBr): ν = 3458 (m), 3368 (m), 3213 (m), 2962 (s),
2935 (s), 2873 (s), 1747 (m), 1721 (w), 1631 (m), 1616 (m),
1505 (w), 1484 (m), 1463 (m), 1400 (w), 1382 (w), 1327 (w),
1280 (w), 1256 (w), 1242 (w), 1215 (w), 1175 (w), 1096 (s),
955 (s), 895 (s), 792 (s, br), 599 (w), 525 (m).
1H NMR (400 MHz, CD3CN): 0.99 (t, 84H,
2JH–H = 7.3,
N(CH2CH2CH2CH3)4), 1.28 (m, 2H, SnCH2), 1.42 (m, 56H,
N(CH2CH2CH2CH3)4), 1.65 (m, 56H, N(CH2CH2CH2CH3)4),
2.75 (m, 2H, CH2CO), 3.16 (m, 56H, N(CH2CH2CH2CH3)4),
6.57, 6.69, 6.88, 7.00, 7.07 (m, 9H, Ar-H), 7.22 (m, 1H, NH).
13C NMR (100 MHz, CD3CN): 2.0 (SnCH2), 14.0
(N(CH2CH2CH2CH3)4), 20.4 (N(CH2CH2CH2CH3)4), 24.5
(N(CH2CH2CH2CH3)4), 32.1 (CH2CON), 59.4 (N(CH2CH2CH2CH3)4),
68.3 (Cquat-fluorescein), 103.4, 108.0, 111.0, 112.8, 113.2,
118.3, 123.0, 125.3, 129.3 & 130.3 (CH-arom.), 150.9 & 153.4
(Cquat-arom.), 159.7 (COO), 170.7 (CH2CON).
31P NMR (121.5 MHz, CD3CN): −12.37 (s, 1P, PW9), −10.27
(s, 1P, PW8Sn).
Elemental analysis (%) calcd. for C119H224KN7O67P2W17Sn
(6170.10 g mol−1):
C 23.16, H 3.66, N 1.59; found: C 22.52, H 3.60, N 1.12.
UV/vis (CH3CN): 257 nm, 289 nm, 458 nm.
UV/vis (PBS): 238 nm, 259 nm, 280 nm, 457 nm, 489 nm.
Ion exchange
Na7[α2-P2W17O61{Sn(CH2)2CONHC20H11O5}]. An exchange
column (diameter 20 mm, length 400 mm) was 50% filled with
a sodium-loaded Amberlite IR-120 cation exchanger.
TBA6K[α2-P2W17O61{Sn(CH2)2CONHC20H11O5}] (50 mg) was
dissolved in CH3CN (1 mL) under sonication and 0.5 mL water
was added. The solution was dropped on the column and
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slowly eluated by a mixture of CH3CN–H2O with increasing
water content. The ratios of CH3CN–H2O were: 1 : 1, 1 : 2, 1 : 4,
1 : 6, 1 : 8, followed by pure H2O. The solvent was removed
under vacuum and the product was obtained as an orange
solid.
Cell viability assay
HeLa cells were seeded onto 96-well plates (Corning) at a
density of 3000 cells per well in DMEM + 10% FCS and kept
overnight under standard conditions (37 °C, 5% CO2, humidi-
fied atmosphere). The medium was replaced by DMEM con-
taining {P2W17O61Fluo} as Na or TBA salt in different
concentrations (50 and 100 µg mL−1), and the cells were incu-
bated for 1, 5 and 24 h. TBA-{P2W17O61Fluo} was first dissolved
in a minimal amount of DMSO and then added to the growth
media with a final concentration of 0.3% (v/v) of DMSO. After
removal of the respective solutions, DMEM containing MTT
(0.5 mg mL−1) was added to the cells. MTT is converted by
living cells after further incubation for 3 h. The metabolic
product formazan was solubilized by replacing the MTT con-
taining medium with dimethyl sulfoxide. After mixing, the
absorption was recorded at 565 nm using a microplate lumino-
meter (synergy2, BioTek). For each concentration and incu-
bation time sextets were performed to determine the standard
deviation. Results are expressed as means ± SD. Data were ana-
lyzed by one-way ANOVA with the post hoc Tukey’s test applied
for paired comparisons (p < 0.05; GraphPad Prism3).
Cellular uptake
HeLa cells were seeded either on 100 mm cell culture dishes or
on PLL pretreated (0.25 mg mL−1 for 1 h, 37 °C) glass cover-
slides overnight. Na-{P2W17O61Fluo} was directly dissolved
in the incubation medium. Experiments with TBA-
{P2W17O61Fluo} were performed similar to MTT assays, i.e. at a
final concentration of 0.3% (v/v) DMSO in DMEM after initial
dissolution of the POM in a minimal volume of DMSO. Cells
were incubated over several periods of time (1, 5 and 24 h)
with 50 and 100 µg mL−1 TBA- and Na-{P2W17O61Fluo},
respectively, diluted in a growth medium (DMEM sup-
plemented with 10% FCS and 1% penicillin/streptomycin) in
two concentrations (50 and 100 µg mL−1) at 37 °C in a 5% CO2
atmosphere. Hoechst (bisbenzimide H, 2 mM) was used for
staining of nuclei. Visualization of mitochondria was per-
formed with 200 nM MitoTracker® Orange CMTMRos. The
individual dyes for CLSM studies were carefully selected to
prevent overlapping of excitation and emission wavelengths.
After incubation times of 30 min for both staining dyes at
37 °C, the cells were washed once with PBS and subsequently
fixed with 1% paraformaldehyde for 15 min at room temp-
erature. The slides were mounted with a Dako ImmunoMount
medium and examined with a confocal laser scanning micro-
scope SP2 (Leica, Germany).
For ICP-MS analysis the cells in 100 mm dishes were
treated as described above for 24 h with 100 µg mL−1 of TBA-
{P2W17O61Fluo}, an equalized amount of unlabeled POM
(K6[P2W18O62]·16H2O) or an equalized amount of fluorescein
amine, respectively. An untreated control was also included.
The cells were detached with Trypsin (Sigma), extensively
washed 3 times with PBS and subsequently lyophilized. Cellu-
lar uptake of tungsten, as the major element in POMs, was
quantified in duplicates with ICP-MS techniques at Mikroana-
lytisches Labor Pascher (Remagen/Germany). In an aliquot of
the sample the protein content was measured in parallel with
the BCA protein assay kit from Pierce according to manufac-
turer’s instructions. Overall POM uptake was calculated and
normalized against the protein content of each sample.
Analytical characterization of the POMs
Fourier transform infrared (FT-IR) spectra were recorded on a
Perkin-Elmer Spectrum Two™ using KBr pellets. UV/vis
spectra were recorded on a PerkinElmer Lambda 650S UV/Vis
spectrometer with a 10 mm cuvette. NMR spectroscopy was
performed on a Bruker AV-2 400 spectrometer. All chemical
shifts are expressed in parts per million (ppm) and referenced
to the residual signals of the solvent.46 In the case of 31P{1H}
NMR spectra the chemical shifts are referenced to H3PO4
(85%) as an external standard. Elemental analysis of the title
compound was carried out on an LECO CHNS-932 Elemental
Analyzer on samples dried in vacuo.
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